Amgen Inc. (BKK:AMGN06)

Market Cap	5.80T +15.9%
Revenue (ttm)	1.17T +10.6%
Net Income	227.48B +65.6%
EPS	420.01 +65.1%
Shares Out	n/a
PE Ratio	25.50
Forward PE	16.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,200
Average Volume	4,090
Open	2.700
Previous Close	2.680
Day's Range	2.700 - 2.700
52-Week Range	2.660 - 2.700
Beta	n/a
RSI	n/a
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: AMGN06

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD